Ponatinib-induced symmetric dermatitis
Ponatinib is a third-generation tyrosine kinase inhibitor (TKI) which is used as a chemotherapeutic agent in the treatment of chronic myeloid leukemia. Despite being relatively less toxic than other older TKIs, it still has various adverse effects including skin rash. Cutaneous manifestations have v...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2022-01-01
|
| Series: | Indian Journal of Drugs in Dermatology |
| Subjects: | |
| Online Access: | http://www.ijdd.in/article.asp?issn=2455-3972;year=2022;volume=8;issue=2;spage=83;epage=85;aulast=Lohani |